Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene pays $710mm up front for Nogra’s Crohn’s disease candidate; deal ends

Executive Summary

Shelling out the largest up-front ever for a biopharma licensing deal, Celgene Corp. paid Nogra Pharma Ltd. (formerly Italian Giuliani International Ltd.; GI, pain, and inflammatory disease therapies) $710mm cash for exclusive rights to GED0301, a late-stage therapy for Crohn’s disease, ulcerative colitis, and other gastrointestinal disorders.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register